Day: ខែ​កក្កដា 25, 2025

Starter Deck 03 ‘Ω to the Future’ marks the highly anticipated debut of Ultraman Omega in card form, featuring exclusive cards and brand new strategies that bring the latest TV series to life and allowing fans to experience the title hero’s journey.Booster Pack 04 ‘Gleam of Eternal Hope’ introduces powerful new versions of iconic Ultra Heroes including Ultraman Dyna, Z, and Trigger. These upgraded cards unlock expanded tactical possibilities, reshaping the game and delivering fresh competitive angles for seasoned players.With the release of both new sets as well as the return of fan-favourite ExP (Extra Parallel) rarity cards, and momentum building toward the Ultra League World Championship 2026, the Ultraman Card Game is poised to grow its global fanbase and strengthen its presence within the trading card game community.KUALA LUMPUR, July 25, 2025 – (ACN Newswire via SeaPRwire.com) – Tsuburaya Productions unveils today the latest additions to the ever-popular Ultraman Card Game – Starter Deck 03 ‘Ω to the Fu…

HONG KONG, July 25, 2025 – (ACN Newswire via SeaPRwire.com) – Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that (Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC.The Approved Product is a multi-dose eye drop formulation containing 3% diquafosol sodium (5ml:150mg), indicated for the treatment of dry eye syndromes such as conjunctival epithelium injury and tear abnormalities. The active pharmaceutical ingredient, diquafosol sodium, is a P2Y2 receptor agonist that acts on conjunctival tissues to promote the secretion of tears containing water and secretory mucins. It may also promote the expression of membrane-bound mucins on corneal epithelium. Boosting the lipid content in tears, it should quantitatively and qualitatively improve tear abnormalities and d…

SHANGHAI, July 25, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the “Sellers”), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue.Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,561,000 shares at a purchase price of HK$69.70 per share, representing:- a discount of approximately 10.12% to the closing price of HK$77.55 per share on July 24, 2025.- a di…

SAN DIEGO, July 24, 2025 – (ACN Newswire via SeaPRwire.com) – International Land Alliance, Inc. (OTCQB: ILAL) (“ILAL” or the “Company”), a global real estate investment and development firm, today announced the launch of a new product offering at its flagship Cabo Oasis and Valle Divino developments in Baja California. With a focus on sustainable design and affordability, this initiative marks a significant expansion of the Company’s master-planned communities.International Land Alliance has identified initial locations within its 500-acre Cabo Oasis beachfront development to introduce Tesla-powered tiny homes. These units are designed to serve as vacation, second, or retirement residences—offered at a purchase price of under $100,000 or a lease option for under $1,000 per month.“We are bringing sustainable, high-quality living to everyone at a price that was once unimaginable,” said Frank Ingrande, President & CEO. “These homes emphasize eco-friendly design, compact efficiency, and cutting-edge technolog…

– The implementation of streamlined approval procedures for Hong Kong- and Macao-registered proprietary Chinese medicines (“pCms”) by mainland China presents significant opportunities for Hong Kong companies to expand into the Greater Bay Area and other mainland market.- A unified and comprehensive registration system strengthens the quality control of Hong Kong’s pCms, reinforcing confidence among other regulatory bodies and stakeholders.- Hong Kong’s first Chinese medicine hospital will gradually commence operations by year end. This will help promote the popularity of Chinese medicine and pCms.HONG KONG, July 24, 2025 – (ACN Newswire via SeaPRwire.com) – The Hong Kong Trade Development Council (“HKTDC”) today released a report, “Challenges and Opportunities in Hong Kong’s Proprietary Chinese Medicine Industry,” that analyses the sector’s development, challenges, and export potential of Hong Kong’s pCm sector. With the completion of the transitional registration process for pCms in June this year, all pCms …